FDA Confirms Detoxi Slim Contains Undeclared Sibutramine in Renewed 2026 Laboratory Testing

Undeclared sibutramine in a commercially available weight-loss product has drawn a renewed FDA public notification, with updated laboratory results confirming the controlled substance remains present in Detoxi Slim as of July 2026, seven years after the agency's initial alert and sixteen years after sibutramine's market withdrawal.

The product, sold by People's Bazaar II and identified across retail and online channels, was first flagged during an examination of international mail shipments in June 2019. FDA laboratory analysis at that time confirmed the presence of sibutramine, a controlled substance withdrawn from the U.S. market in October 2010 due to cardiovascular safety concerns. Sibutramine is known to substantially increase blood pressure and heart rate, presenting elevated risk for patients with coronary artery disease, congestive heart failure, arrhythmias, or prior stroke, and carries potential for life-threatening interactions with concomitant medications.

For QA directors and supply chain leads, the persistence of this product across distribution channels over a multi-year span underscores a documented gap in third-party and imported product oversight. The original detection through international mail interception points directly to the import examination process as a control point, but the product's continued availability in retail and online environments indicates that downstream verification has not closed the loop. Under 21 CFR Part 111, dietary supplement manufacturers and distributors bear responsibility for identity verification of incoming materials; the Detoxi Slim case illustrates what happens when that control is absent or bypassed at the retail distribution tier.

FDA has acknowledged it cannot test and identify all potentially adulterated products marketed as dietary supplements, a statement that places the practical burden of vigilance on industry stakeholders. For regulatory affairs leads monitoring product portfolios that include third-party or imported items, this notification reinforces the case for supplier qualification programs and label verification protocols aligned with ICH Q10 pharmaceutical quality system principles, even where those standards are not formally mandated for the supplement category.

Healthcare professionals and patients are directed to report adverse events through FDA's MedWatch Safety Information and Adverse Event Reporting Program, either via the online voluntary reporting form or by fax at 1-800-FDA-0178.

The 2026 reconfirmation of sibutramine in Detoxi Slim sets a measurable reference point: whether People's Bazaar II and associated retail channels remove the product from commerce will be a traceable outcome against which FDA's enforcement follow-through can be assessed.

Source: U.S. Food and Drug Administration, Medication Health Fraud Notifications, via FDA.gov, August 11, 2026; original notification dated June 26, 2019; updated laboratory testing result dated July 14, 2026.